Table 2.
Study | APC, % | BRAF, % | PIK3CA, % | KRAS, % | TP53, % |
---|---|---|---|---|---|
Katkoori et al (2009)86 | 68/137 (49.6) | ||||
Sylvester et al (2012)74 | 6/170 (3.5) | 57/170 (33.5) | |||
Xicola et al (2014)76 | 16/408 (3.9) | 44/192 (22.9) | |||
Ashktorab et al (2015)84 | 8/12 (66.7) | 1/12 (8.3) | 2/12 (16.7) | 6/12 (50) | 2/12 (16.7) |
Guda et al (2015)85 | 22/29 (75.9) | 2/29 (6.9) | 5/29 (17.2) | 16/29 (55.2) | 20/29 (69) |
Kang et al (2013)∗87 | – (18) | – (28.3) | – (68.5) |
Data are given as number/total (percentage). None of the cited reports claimed that the frequencies of the driver mutations tested in African American colorectal cancers were significantly different from the frequencies reported for white driver mutations. Empty cells indicate that the gene was not tested in the study.
n = 67.
–, numerators were not provided in the article.